CONSTITUTION OF THE CLINICAL BOARD AND DESIGN OF A PROSPECTIVE OBSERVATIONAL STUDY

Hemera’s Clinical Board has been established; the board include Neurosurgery and Neurorehabilitation experts from Milan Niguarda, Milan Humanitas, Bergamo, Brescia, Como, Novara, and Varese Medical Centers. The Clinical Board is intended as a working group of clinical-scientific consultants, which supports Hemera in identifying the best strategies for planning clinical trials, especially in defining spinal cord-injured patients’ inclusion/exclusion criteria. The Clinical Board met the Hemera’s Team at Niguarda Hospital (Milan) on September 13 for a joint evaluation of a prospective observational study on patients with complete spinal trauma, expected to start in Spring 2023. Currently, the primary objective of the study, the secondary objectives, the number of patients to be enrolled, the criteria for patients’ inclusion and exclusion, the duration of the study, and the parameters to be monitored are being defined.

VERONA NETWORK AWARD

In July, Hemera was assigned the Verona Network Award “for having developed an innovative therapy aimed at regenerating damaged nervous tissue and for having carried out a precious collection of capital for future research developments”.

SVILUPPO ORGANIZATIONAL DEVELOPMENT

In July-September, the Clinical Development Management team was enriched with new professional figures, including biostatisticians and clinical writers, necessary to launch the prospective observational study. In September, two positions were also opened for scientist working in the field of regenerative medicine for neurological disorders. The application deadline is October 25 and, as of September 30, 23 applications have been received.

FUNDRAISING

Just over 12 months after its establishment, Hemera has raised a total of over 2 million euros: a significant milestone that represents the tangible sign of the generosity of our members combined with the scientific and entrepreneurial qualities of Hemera’s project. The raising of capital continues; the new round will end on November 30.